Accessing our website tells us you are happy to receive all our cookies. However you can change your cookie settings at any time.

Privacy & Cookies

You are leaving our website

You have clicked on a link that will take you to a third-party website that Alliance Pharmaceuticals plc group (“Alliance”) is not responsible for.

Please read the following disclaimer and click “I agree” to proceed to the third-party website.

By clicking to continue you agree that:You are leaving Alliance`s website.

Alliance:

  • Is not responsible for the content or accuracy of the third-party website nor endorse or guarantee any services or information they may offer.
  • Does not represent either the third-party website or you (the visitor) if you enter into an agreement or transaction.
  • Privacy and security policies do not apply to third-party websites.
or Decline

Our Financial Highlights for 2020

The Group continued to deliver a robust operational and financial performance in 2020, despite the challenges posed by COVID-19.

We saw strong performance from our Consumer Healthcare brands, which now account for over two thirds of Group see-through revenues*

Kelo-cote™ revenues up 12%

Nizoral™ see-through revenues* up 4%

See-through revenues* overall up 1% to £93.0m (2019: £92.4m)

To view in detail click here to download our 2020 Annual Report

currently counter number sum counter number

See-through revenue*

currently counter number sum counter number

Statutory Revenue

currently counter number sum counter number

Underlying Profit Before Tax

currently counter number sum counter number

Reported Profit Before Tax

currently counter number sum counter number

Underlying Basic EPS**

currently counter number sum counter number

Reported Basic EPS

currently counter number sum counter number

Free Cash Flow*

currently counter number sum counter number

Net Debt

Five Year Summary
Year ended 31 December 2016 £mYear ended 31 December 2017 £mYear ended 31 December 2018 £mYear ended 31 December 2019 £mYear ended 31 December 2020 £m
Revenue97.5101.6118.2135.6129.8
Operating profit before non-underlying items25.625.828.937.436.8
Non-underlying operating items-4.4(5.3)(1.8)(20.5)
Operating profit25.630.223.735.616.3
Profit before tax before non-underlying items22.223.928.132.933.5
Profit before tax after non-underlying items22.228.322.831.113.0
Intangible assets264.8278.6335.2328.7412.9
Tangible assets1.85.77.611.615.9
Current assets49.349.158.765.077.2
Current liabilities50.361.491.724.230.2
Equity179.3203.1252.2274.2281.0
Average shares in issue (millions)469.4473.8497.2520.7531.1
Shares in issue at period end (millions)472.6475.0518.2529.4532.9
Earnings per share – basic (p)3.856.083.694.801.51
Earnings per share – adjusted underlying basic (p)3.694.054.545.095.11

* Non-IFRS alternative performance measures (see note 33). See-through revenue includes sales from Nizoral as if they had been invoiced by Alliance. For statutory accounting purposes the product margin on Nizoral sales is included within Revenue, in line with IFRS 15